Video

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma (RCC).

It is time to revisit vaccines, Hammers says, particularly in combinations. Approaches to this include allogenic vaccines for easy, over-the-counter use, and tailor-made vaccines to fit the needs of a specific patient.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center